Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy

Study Overview
=================
Brief Summary
-----------------
Post-authorization, prospective follow-up, multi-centre, national study to estimate definitive deterioration in the quality of life in patients with metastatic breast cancer treated with second-line monochemotherapy.

Detailed Description
-----------------
Post-authorization, prospective, multi-centre study in Metastatic Breast Cancer patients treated with second-line monochemotherapy. A total of 200 patients are expected to be recruited from 32 Spanish sites. In this study the results perceived by patients will be compiled to assess overall Quality of Life (QoL) in MBC patients treated with second-line monochemotherapy, using the EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) and its modules EORTC QLQ-BR23 (EORTC Breast Cancer specific) and EORTC QLQ-CIPN20 (EORTC Chemotherapy-Induced Peripheral Neuropathy). Patients will be evaluated at the time of acceptance to participate in the study after signing the informed consent and will be tracked every three months during treatment with second-line monochemotherapy, coinciding with routine assessments within normal clinical practice. When the patient completes treatment with second-line chemotherapy he/she will enter the post-treatment period, with follow-up at six and 12 months after completion of treatment. Also, patients will be followed to assess survival until the end of the study (30 months after enrolment of the last patient in the study). Follow-up time has been established based on the median survival of patients with MBC

Official Title
-----------------
Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy

Conditions
-----------------
Breast Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who give their written informed consent. Patients with metastatic breast cancer who start treatment with second-line monochemotherapy. Patients of both sexes, at least 18 years of age and of any race. Patients with life expectancy longer than or equal to 12 weeks. Patients with histological or cytological diagnosis of Her-2/neu negative breast adenocarcinoma. Patients with ability enough to understand the questionnaires. Exclusion Criteria: Pregnant or lactating women. Patients who have been treated with chemotherapy in the last three weeks Patients who refuse to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Definitive deterioration at 6 months | Proportion of patients with definitive deterioration at six months after initiation of second-line mono-chemotherapy for MBC | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Definitive deterioration at 3 months | Description Proportion of patients with definitive deterioration at 3 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons | 3 Months | 
| Definitive deterioration at 9 months | Proportion of patients with definitive deterioration at 9 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons | 9 Months | 
| Definitive deterioration at 12 months | Proportion of patients with definitive deterioration at 12 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons | 12 Months | 
| Time to Definitive deterioration (TTDD) | Estimated median TTDD using the actuarial method | Up to 42 months | 
| Overall survival | Estimated overall survival using the Kaplan-Meier method | Up to 42 months | 
| TTDD as a prognostic factor | Determine if TTDD is an independent prognostic factor for overall survival using Cox regression. | Up to 42 months | 
| Quality of life | Comparison of the mean score of the scales of the EORTC QLQ-C30, EORTC QLQ-BR23 and between patients ≥70 years and <70 years at baseline, every 3 months approximately and at the time of disease progression or completion of treatment for other reasons | Up to 42 months | 
| Quality of life every 3 months | Score in the scales of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires at baseline, every 3 months approximately and at the time of disease progression or completion of treatment for other reasons. | Up to 42 months | 
| Chemotherapy-induced peripheral neuropathy | Incidence, management and duration of chemotherapy-induced peripheral neuropathy at baseline, every 3 months approximately up to disease progression and at 6 and 12 months after completion of second-line chemotherapy | Up to 42 months | 
| Chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20 | Assess the effect of chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20 quality of life questionnaire at baseline, every 3 months approximately up to disease progression or completion of treatment for other reasons and at 6 and 12 months after completion of second-line chemotherapy | Up to 42 months | 
| Definitive deterioration | Comparison of the proportion of patients with definitive deterioration at every 3 months approximately up to disease progression or completion of treatment for other reasons in patients with ECOG 0-1 and ECOG 2-3, using the chi-squared test. | Up to 42 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metastatic breast cancer, Monotherapy, chemotherapy, second line, treatment, Her 2 negative